Kaia Health Unveils Complete Musculoskeletal Care Solution with Kaia Gateway and Premium Partners

February 10, 2021

Kaia Health

Kaia Health, announces Kaia Gateway and Premium Partners, the next-generation complete MSK care solution for all U.S. employers and health plans, based on the industry’s largest randomized controlled trial (RCT), which showed how a treatment path, combining digital therapy, personalized health coaching and a collaboration with medical providers, achieved better outcomes than standard of care.

Kaia Health’s digital MSK program has already treated 450,000 patients to date. Their complete MSK care solution will feature a rigorous claims-based ROI for each client and support preventative, acute, chronic and presurgical care for total spine, hip, knee, shoulder, hand, wrist, foot, and ankle. These capabilities will be fully rolled out by January 2022.

Kaia Health

 

 

 

 

Introducing the all-new Kaia Gateway

Kaia Gateway is the new front door for all MSK patients and accessed via Kaia Health’s existing digital MSK program.

A clinical triage algorithm will screen each patient and direct those at risk of needing more invasive or intense treatment to a Kaia Health medical provider for case review. An AI-enabled escalation algorithm will monitor patients longitudinally for clinical and behavioral patterns, mitigating the risk of unnecessary elective, and often costly, surgery.

The algorithms feature Kaia Health’s patented Motion Coach™ computer vision technology, which, using a smartphone, tracks thousands of data points on a patient’s body and provides real-time exercise feedback. This creates a more personalized, engaging experience than sensor straps or periodic video chats.

“Kaia Gateway creates an unprecedented level of understanding of MSK patients and their progression,” says Justin Yang, Kaia Health’s U.S. Chief Medical Officer. “The algorithms now include Motion Coach™ data in addition to self-reported and adherence data. Motion Coach™ thus now drives our clinical decision making in addition to patient engagement. This richer dataset will offer a more informed user case review and allow Kaia Gateway to make better patient choices in the treatment app or via one of our partners.”

Introducing Premium Partners

Today, Kaia Health coaches refer out to other medical services within employers’ ecosystems. Premium Partners represent a deeper level of partner integration. They will be closely tied to Kaia’s existing MSK treatment and have access to detailed treatment history, including Motion Coach™ insights and disease progression. It will also feature other care solutions, including digital interventions, PT and telemedicine.

In a recent regional health system deployment, Kaia Health’s MSK app use resulted in a 22% medical claims net cost savings and 50% decrease in MSK pain level. For employers, Kaia Health’s MSK app has demonstrated more than 20% decrease in medical spend with a 1.6x – 3x average ROI in the first year.

MSK conditions affect 126.6 million Americans, which result in annual costs to U.S. employers of $120 billion. MSK costs business an average of $425 per member per year in medical bills, affects 25% of their workforce and accounts for 16% of overall medical spend.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”